Autogene cevumeran
- Generic Name
- Autogene cevumeran
- Drug Type
- Biotech
- CAS Number
- 2365453-34-3
- Unique Ingredient Identifier
- L8HDH9IB06
- Background
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
- Conditions
- Muscle Invasive Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 362
- Registration Number
- NCT06534983
- Locations
- π©πͺ
Uniklinik-Eppendorf, Hamburg, Germany
π©πͺUniklinikum Heidelberg, Heidelberg, Germany
π©πͺMarien Hospital Herne, Herne, Germany
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
- Conditions
- Adenocarcinoma, Pancreatic Ductal
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05968326
- Locations
- π°π·
Severance Hospital - Yonsei Cancer Center, Seoul, Korea, Republic of
π°π·University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC), Songpa-gu, Korea, Republic of
πΊπΈUSC Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04267237
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT04161755
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities), Commack, New York, United States
πΊπΈMemorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
πΊπΈMemorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT03815058
- Locations
- πΊπΈ
Seattle Cancer Care Alliance, Seattle, Washington, United States
π¦πΊLiverpool Hospital, Liverpool, New South Wales, Australia
πΊπΈAtlanta Cancer Care, Alpharetta, Georgia, United States
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Conditions
- MelanomaTriple Negative Breast CancerRenal CancerBladder CancerColorectal CancerNon-Small Cell Lung CancerOther Solid CancersHead and Neck Cancer
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03289962
- Locations
- πΊπΈ
Dana Farber Can Ins, Boston, Massachusetts, United States
π¨π¦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
π¨π¦Princess Margaret Cancer Center, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.